T1D group for Type 1 Diabetes Mellitus

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Type 1 Diabetes Mellitus+1 More
Metabolic testing - Other
Eligibility
18 - 65
All Sexes
What conditions do you have?
Select

Study Summary

This trial will compare how type 1 diabetes affects apolipoprotein and triglyceride levels, which are risk factors for heart attack and stroke.

Eligible Conditions
  • Type 1 Diabetes Mellitus

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Type 1 Diabetes Mellitus

Study Objectives

1 Primary · 5 Secondary · Reporting Duration: one time, at baseline (this is a cross-sectional, observational study, no intervention)

one time, at baseline (this is a cross-sectional, observational study, no intervention)
Apolipoprotein B-100 concentration
Apolipoprotein B-100 turnover rate
Apolipoprotein C concentration
Apolipoprotein C turnover rate
Triglyceride concentration
Triglyceride turnover rate

Trial Safety

Safety Progress

1 of 3

Other trials for Type 1 Diabetes Mellitus

Trial Design

1 Treatment Group

T1D group
1 of 1
Active Control

30 Total Participants · 1 Treatment Group

Primary Treatment: T1D group · No Placebo Group · N/A

T1D group
Other
ActiveComparator Group · 1 Intervention: Metabolic testing · Intervention Types: Other

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: one time, at baseline (this is a cross-sectional, observational study, no intervention)

Who is running the clinical trial?

University of WashingtonOTHER
1,583 Previous Clinical Trials
1,565,956 Total Patients Enrolled
2 Trials studying Type 1 Diabetes Mellitus
298 Patients Enrolled for Type 1 Diabetes Mellitus
Washington University School of MedicineLead Sponsor
1,789 Previous Clinical Trials
2,271,846 Total Patients Enrolled
9 Trials studying Type 1 Diabetes Mellitus
488 Patients Enrolled for Type 1 Diabetes Mellitus
Bettina MittendorferPrincipal InvestigatorWashington University School of Medicine
1 Previous Clinical Trials
60 Total Patients Enrolled

Eligibility Criteria

Age 18 - 65 · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
Plasma glucose > 140 mg/dL at 2 h after a 75 g oral glucose challenge.
You are aged 18 to 45 years.\n
You have a fasting plasma triglyceride level of 150 mg/dL or less.
You have a fasting plasma glucose level of 100 mg/dL or less.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 7th, 2021

Last Reviewed: October 4th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.